699 results about "Mrna expression" patented technology

The present inventors have shown that the gene and protein expression profiles of ADAM8, ADAM10 and ADAM12 in different grades and stages of bladder cancer.

ADAM12 gene expression was evaluated in tumors from 96 patients with bladder cancer using a customized Affymetrix GeneChip. Gene expression in bladder cancer was validated using reverse transcription-polymerase chain reaction (RT-PCR), quantitative PCR, and in situ hybridization. Protein expression was evaluated by immunohistochemical staining on tissue arrays of bladder cancers.

The presence and relative amount of ADAM12 in the urine of cancer patients were determined by Western blotting and densitometric measurements, respectively.

Particularly ADAM12 mRNA expression was significantly upregulated in bladder cancer, as determined by microarray analysis, and the level of ADAM12 mRNA correlated with disease stage. ADAM12 protein expression correlated with tumor stage and grade. ADAM12 was present in higher levels in the urine from bladder cancer patients than in urine from healthy individuals. Significantly, following removal of tumor by surgery, in most bladder cancer cases examined the level of ADAM12 in the urine decreased and, upon recurrence of tumor, increased.

The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided.

Multiple modality contrast can be used to produce images that can be combined and rendered to produce images similar to those produced with wavelength absorbing stains viewed under transmitted white light illumination. Images obtained with other complementary contrast modalities can be presented using engineered color schemes based on classical contrast methods used to reveal the same anatomical structures and histochemistry, thereby providing relevance to medical training and experience. Dark-field contrast images derived from refractive index and fluorescent DAPI counterstain images are combined to produce images similar to those obtained with conventional H&E staining for pathology interpretation. Such multi-modal image data can be streamed for live navigation of histological samples, and can be combined with molecular localizations of genetic DNA probes (FISH), sites of mRNA expression (mRNA-ISH), and immunohistochemical (IHC) probes localized on the same tissue sections, used to evaluate and map tissue sections prepared for imaging mass spectrometry.

An analytic apparatus and method is provided for diagnosis, prognosis and biomarker discovery using transcriptome data such as mRNA expression levels from microarrays, proteomic data, and metabolomic data. The invention provides for model-based analysis, especially using kernel-based models, and more particularly similarity-based models. Model-derived residuals advantageously provide a unique new tool for insights into disease mechanisms. Localization of models provides for improved model efficacy. The invention is capable of extracting useful information heretofore unavailable by other methods, relating to dynamics in cellular gene regulation, regulatory networks, biological pathways and metabolism.

RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.

The invention relates to a method for achieving HMGCR gene knockout based on the CRISPR/Cas9 technology. The method is characterized in that two CRISPR/Cas9 target sequence aiming at the HMGCR gene isdesigned, a gRNA single chain is synthesized in vitro, annealing is performed to obtain two gRNA double-chain DNA target insertion fragments, the insertion fragments are inserted into PX459 (pSpCas9(BB)-2A-Puro)V2.0 vectors to obtain the two different-locus plasmids of the target HMGCR gene; the two plasmids are transfected into PK15 cells, puromycin is used to process the cells, the processed cell genome DNA is extracted to perform PCR amplification, the PCR product is denatured, annealing is performed, and then T7E1 is used to perform HMGCR gene knockout identification. The method has the advantages that method can be used for analyzing the expression conditions of sequence and mRNA after the HMGCR gene knockout, whether an off-target phenomenon exists or not can be verified by using amethod combining PCR and T7E1 enzyme treatment, and accordingly the specificity based on target sequence HMGCR-gRNA can be determined; the method is applicable to cell and animal models to achieve fixed-point HMGCR gene knockout, has a reference value to the knockout of other genes, and is good in effect, simple, economical, short in time and the like.

Disclosed herein are cloning vectors which include: (a) a cloning site which permits the cloning of a nucleic acid in defined orientation; (b) at least one cleavage site adjacent to the cloning site, the cleavage site being rarely-occurring in nucleic acids; and (c) a long region which is located on the side of the cloning site opposite to the cleavage site (b), wherein the long region and the region between the cloning site and the cleavage site (b) contain neither the cloning site nor at least two frequently-occurring cleavage sites.

The present invention provides compositions and methods for simultaneously detecting mRNA expression levels of hormonal receptors, particularly both estrogen receptor (ER) and progesterone receptor (PR), optionally in combination with growth factor receptors, particularly epidermal growth factor receptor ERBB2 (Her-2), and further optionally in combination with control genes, such as the housekeeping genes NUP214 and/or PPIG. Exemplary embodiments of the invention are useful for determining hormonal receptor and/or growth factor receptor status, particular both ER and PR status and optionally also ERBB2 status, such as for assessing or treating breast cancer.

RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.

RNA interference, is provided for inhibition of HIF1A mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

The present invention generally relates to methods, systems and computer readable media for the diagnosis and/or prognosis of a cardiac stress and/or skeletal muscle stress in a subject. In particular, in one embodiment, the methods, systems and computer readable media detect a level of Fstl expression, such as Fstl1 polypeptide or mRNA expression in a biological sample obtained from a subject, where a high level relative to a reference Fstl expression level is indicative of a subject having, or is at risk of cardiac stress and/or skeletal muscle stress. In such embodiments, the method futher comprises administering or undertaking an appropriate therapy in a subject identified to have or be at risk of cardiac stress and/or skeletal muscle stress. Another aspect of the present invention relates to the methods, systems and computer readable media detect a level of Fstl expression, such as Fstl1 polypeptide or mRNA expression in a biological sample obtained from a subject where a low level relative to a reference Fstl expression level is indicative of a subject having, or is at risk of diabetes and/or metabolic dysfunction. In such embodiments, the method futher comprises administering or undertaking an appropriate therapy in a subject identified to have or be at risk of diabetes and/or metabolic dysfunction.

The invention belongs to the field of pharmacy, and relates to application of a hydrogen sulfide donor to the preparation of a medicine for treating central nervous system disease, in particular to application of the hydrogen sulfide donor, namely sodium hydrosulfide, or allyl cysteine and analogues thereof to the preparation of the medicine for treating the central nervous system disease. Integral animal model experiments prove that the sodium hydrosulfide and propargyl cysteine can reduce the learning and memory impairment of rats, increase the content of hydrogen sulfide in hippocampus tissues of the rats, inhibit the messenger ribonucleic acid (mRNA) expression of a tumor necrosis factor alpha and a receptor I thereof, inhibit an inflammatory mediator in the hippocampus tissues of rats with dementia and inhibit inflammation-related enzymes in the hippocampus tissues of the rats, and can be used as a medicine for treating Alzheimer disease and other inflammation-related central nervous system degenerative diseases such as Parkinson disease.

This invention pertains to the discovery that brain-derived neurotrophic factor (BDNF) and its associated signaling pathway is involved in reversing and/or counteracting neuroadaptations within the mesolimbic system that contribute to the development and/or maintenance of addiction (e.g. alcohol addiction). This invention also pertains to the discovery that ibogaine activity is mediated by changes in mRNA expression of GDNF. Thus, in certain embodiments, this inventioni provides a method of mitigating one or more symptoms of substance abuse in a mammal by increasing the expression or activity of GDNF, BDNF, RACK1, and/or the dopamine D3 receptor (D3R) in said mammal.

The invention discloses a liquid phase chip for detecting breast cancer prognosis-related gene mRNA expression level, which mainly comprises a microsphere which aims at different target genes and is coupled to amido modified supporting probes, supporting extended probes connecting the supporting probes and target gene mRNA and amplification extended probes. Each supporting probe mainly comprises a 5' end spacer arm sequence and a 3' end specific sequence P1 which is in complementary pairing with a supporting extended probe; the supporting probe comprises SEQ. ID NO.1 specific to ESR1gene and SEQ. ID NO.2 specific to PGR gene; each supporting extended probe mainly comprises a 5' end specific sequence P2 which can be correspondingly combined with the target genes, a spacer arm sequence and a 3' end specific sequence P3 which is in complementary pairing with the specific sequence P1 of a corresponding supporting probe; and the supporting extended probes comprise amplification extended probes, wherein each amplification extension probe comprises a 5' end specific sequence P4 which can be combined with the target genes, a spacer arm sequence and a 3' end sequence P5; or the liquid phase chip also comprises a labeling probe in complementary pairing with the sequence P5. The liquid phase chip can perform hybridization reaction under the homogeneous reaction condition, and the designed probes have the advantages of high specificity and high signal to noise ratio during detection.

RNA interference is provided for inhibition of serum amyloid A mRNA expression in glaucomas involving SAA expression.

The invention discloses a method and a system for discovering and integrating rectal cancer related genes by utilizing public data resources and analyzing functions of the rectal cancer related genes, and an application. Based on the public data resources, open big data resources and diversified bioinformatics analysis means are reasonably used for performing analysis processing on mRNA expression data, and important genes related to complex diseases and functions of the important genes are identified. The method comprises the steps of sample data downloading and management; gene expression data analysis; difference expression gene screening; and gene function analysis and protein interaction analysis. According to the method and the system, the problems of weakness in integrating existing network resources, unfamiliarity with mRNA related most common databases and frontal analysis methods, incapability of independently finishing mRNA expression spectrum related bioinformatics analysis and the like can be solved; a plurality of risk pathways and genes related to the complex diseases such as the rectal cancer and the like can be discovered; and the method and the system are of important significance for biological targeted treatment of the complex diseases, biological drug research and development, pathogenesis explanation and risk prediction.

The invention discloses a lung cancer detection marker and a diagnostic kit, application of exosome CD171 protein to preparation of lung cancer diagnostic kits as a detection target spot, and application of a reagent for detecting the expression quantity of exosome CD171 protein to preparation of the lung cancer diagnostic kits. A real-time fluorescent PCR detection reagent for detecting the mRNAexpression quantity of the exosome CD171 protein preferably contains qPCR primers for detecting the exosome CD171 protein, wherein an upstream primer sequence is as shown in SEQ ID NO.1, and a downstream primer sequence is as shown in SEQ ID NO.2. The invention discloses the exosome CD171 protein, which can be used for diagnosing whether a patient suffers from lung cancer by detecting the proteinexpression level of CD171. Proved by experiment, the CD171 protein can effectively distinguish a person of lung cancer from a healthy person. Therefore, the invention provides a new detection target spot for the early diagnosis detection of lung cancer.

The present invention provides polynucleotides having chemistry patterns that provide for improved stability, potency, and/or toxicity relative to their use as miRNA inhibitors or miRNA mimetics. The invention further provides pharmaceutical compositions and formulations comprising the polynucleotides, and methods for treating patients having a condition associated with miRNA or mRNA expression.